Fast Facts: Cholangiocarcinoma

C. Braconi, R.T. Shroff

Description

Cholangiocarcinomas (CCAs) are a group of heterogeneous tumors that have traditionally had poor prognosis. Despite being rare, the global incidence of CCA has increased dramatically over the last few decades. However, alongside this, there have been advancements in our understanding, diagnosis and treatment, improving the overall survival and quality of life of patients with advanced disease. This compact yet comprehensive review of CCA serves as a guide for physicians, oncologists, allied health professionals, scientists, patients and caregivers to update their knowledge of the most recent clinical developments and most promising areas of research. Table of Contents: • Pathophysiology, etiology and epidemiology • Diagnosis • Biliary drainage and supportive care • Surgical resection and transplantation • Translational research • Systemic therapy • Immunotherapy • Radiotherapy and photodynamic therapy

Informations

• Publié par: S. Karger AG
• Date de parution: 08 avril 2021
• Nombre de lectures: 0
• EAN13: 9783318068108
• Langue: English
• Poids de l'ouvrage: 1 Mo

Extrait

Fast Facts: Cholangiocarcinoma First published 2021
Text 2021 Rachna T Shroff, Chiara Braconi
2021 in this edition S. Karger Publishers Ltd
S. Karger Publishers Ltd, Elizabeth House, Queen Street, Abingdon, Oxford OX14 3LN, UK Tel: [phone]
Book orders can be placed by telephone or email, or via the website. Please telephone [phone] or email [e-mail] To order via the website, please go to karger.com
Fast Facts is a trademark of S. Karger Publishers Ltd.
All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without the express permission of the publisher.
The rights of Rachna T Shroff and Chiara Braconi to be identified as the authors of this work have been asserted in accordance with the Copyright, Designs Patents Act 1988 Sections 77 and 78.
The publisher and the authors have made every effort to ensure the accuracy of this book, but cannot accept responsibility for any errors or omissions.
For all drugs, please consult the product labeling approved in your country for prescribing information.
Registered names, trademarks, etc. used in this book, even when not marked as such, are not to be considered unprotected by law.
A CIP record for this title is available from the British Library.
ISBN 978-3-318-06809-2
Shroff RT (Rachna) Fast Facts: Cholangiocarcinoma/ Rachna T Shroff, Chiara Braconi
Medical illustrations by Graeme Chambers, Belfast, UK. Typesetting by Amnet, Chennai, India.
Printed in the UK with Xpedient Print.
An independent publication developed by S. Karger Publishers Limited and provided as a service to medicine. Supported by an educational grant from Agios.
Contents
List of abbreviations
Introduction
Pathophysiology, etiology and epidemiology
Diagnosis
Biliary drainage and supportive care
Surgical resection and transplantation
Translational research
Systemic therapy
Immunotherapy
Radiotherapy and photodynamic therapy
Useful resources
Index
List of abbreviations
AAPC: average annual percent change
ADP: adenosine diphosphate
AE: adverse event
ASC: active symptom control
ASCO: American Society of Clinical Oncology
CA19-9: carbohydrate antigen 19-9
CCA: cholangiocarcinoma
CEA: carcinoembryonic antigen
CI: confidence interval
CT: computed tomography
ctDNA: circulating tumor DNA
CTLA-4: cytotoxic T-lymphocyte-associated protein 4
dCCA: distal cholangiocarcinoma
DCR: disease control rate
DNA: deoxyribonucleic acid
eCCA: extrahepatic cholangiocarcinoma
ERCP: endoscopic retrograde cholangiopancreatography
ESAS-FWB: Edmonton Symptom Assessment Scale-Feeling of Well-Being
EUS: endoscopic ultrasound
FC-SEMS: fully covered self-expanding metal stents
FDA: (US) Food and Drug Administration
FGFR: fibroblast growth factor receptor
FLR: future liver remnant
FOLFIRI: fluoropyrimidine + irinotecan
FOLFOX: fluoropyrimidine + oxaliplatin
HER2: human epidermal growth factor receptor 2
HIV: human immunodeficiency virus
HR: hazard ratio
iCCA: intrahepatic cholangiocarcinoma
ICI: immune checkpoint inhibitor
IDH: isocitrate dehydrogenase
Ig: immunoglobulin
miRNA: microRNA
MMR: mismatch repair
MRCP: magnetic resonance cholangiography
MRI: magnetic resonance imaging
MSI(-H): microsatellite instability (high)
NAFLD: non-alcoholic fatty liver disease
ncRNA: non-coding RNA
NCT: National Clinical Trials number
OLT: orthotopic liver transplantation
OR: odds ratio
ORR: overall response rate
OS: overall survival
p53 : tumor suppressor protein 53 [gene]
PARP: poly(ADP-ribose) polymerase
pCCA: perihilar cholangiocarcinoma
PD-1: programmed cell death protein 1
PD-L1: programmed death-ligand 1
PDO: patient-derived organoid
PDT: photodynamic therapy
PET: positron emission tomography
PFS: progression-free survival
PSC: primary sclerosing cholangitis
PTC: percutaneous transhepatic cholangiography
R1: margin-positive
RCT: randomized controlled trial
RNA: ribonucleic acid
SBRT: stereotactic body radiotherapy
SEER: Surveillance, Epidemiology, and End Results
SEMS: self-expanding metal stent
SIRT: selective internal radiotherapy
TMB: tumor mutational burden
U-SEMS: uncovered self-expanding metal stents
Introduction
Cholangiocarcinomas (CCAs) are a group of heterogeneous tumors that have traditionally had poor prognosis. Despite CCA being rare, its global incidence has increased dramatically over the last few decades. In turn, the oncology community s engagement with patients with CCA has grown over the last 10 years as a consequence of increased epidemiological data, improved diagnostic technologies and greater awareness.
Advancements in our understanding of biology and the characterization of the genomic landscape of CCA have led to the development of novel therapeutics and positive progress in clinical management. The adoption of updated coding and classification systems, approval of novel therapies and identification of molecular features have opened up the possibility of personalized oncology.
Over the last decade, targeted agents have improved the overall survival and quality of life of patients with advanced disease. Some of these agents may emerge as chemotherapy-free first-line options. New cytotoxic treatments are also under investigation for patients who lack targetable alterations; ongoing studies of immunotherapy have shown benefits in selected populations, warranting further investigation into optimal patient selection strategies and efficacy. Advances in adjuvant and neoadjuvant therapies, as well as surgical and radiation techniques, have also resulted in clinically meaningful benefits. Nonetheless, a number of unmet needs continue to pose challenges to the research community. These include the development of plans for early diagnosis, the identification of biomarkers of chemotherapy sensitivity, strategies to overcome drug resistance, the establishment of preclinical models to boost scientific discoveries and the individualization of treatment.
This compact yet comprehensive review of CCA serves as a guide for physicians, oncologists, allied health professionals, scientists, patients and caregivers to update their knowledge of the most recent clinical developments and most promising areas of research. With many novel therapeutics and combination therapies on the horizon, the coming decade will surely bring pivotal advancements in the treatment and management of CCA.
1 Pathophysiology, etiology and epidemiology
Pathophysiology
CCAs are a heterogeneous group of malignancies that arise from the epithelium of the biliary tract, 1 which consists of intra- and extrahepatic bile ducts.
Bile drains from the gallbladder into the extrahepatic bile duct through the cystic duct for transport to the duodenum. The left and right hepatic ducts (and their first three branches) are referred to as the hilar and perihilar bile ducts. 2 , 3 They are grossly visible and are also known as large intrahepatic bile ducts. The remaining bile ducts within the liver parenchyma that are proximal to the left and right hepatic ducts are referred to as small intrahepatic bile ducts. Together with glandular structures they form the complex biliary drainage network ( Figure 1.1 ). 1-4
Classification. CCAs are classified based on their anatomic location. 3 Intrahepatic CCAs (iCCAs) arise from ductal epithelium within the liver parenchyma, while extrahepatic CCAs (eCCAs) are divided into perihilar CCAs (pCCAs, previously known as Klatskin tumors), which arise at the junction between second-order bile ducts and the cystic duct, and distal CCAs (dCCAs), which arise in the region between the cystic duct and the ampulla of Vater. 3 , 5-7 It is increasingly evident that these tumors have a great degree of inter- and intratumor heterogeneity, which has important implications for patient treatment and prognosis.
Histological subtypes. The majority of CCAs are adenocarcinomas. Histologically, iCCAs have features of acini, papillary and tubular structures and are further subclassified into small- and large-bile duct types based on their anatomic cells of origin. 2 , 3 , 8 , 9
The small-bile duct subtype is characterized by epithelial cells of columnar to cuboidal morphology, with nodular growth patterns and infiltration into the liver parenchyma. These tumors are typically well or moderately differentiated. Poorly differentiated CCAs have more cribiform growth with nuclear and cellular pleomorphism.

Figure 1.1 Anatomic locations of CCAs.
The large-bile duct subtype is characterized by flat, papillary structures with luminal spread. Other histological variants include squamous cell carcinoma, which features keratinization and is typically well differentiated, 2 , 3 and adenosquamous cell carcinoma, which contains features of adenocarcinoma and squamous cell carcinoma intermixed or isolated within the tumor. The mucinous subtype is characterized by carcinoma cells within regions of mucin and sometimes has signet ring cell features.
Other histological subtypes include clear cell, lymphoepithelioma-like, neuroendocrine, sarcomatous and anaplastic types. Cytokeratins 7 and 19 and epithelial membrane antigen are immunohistochemical markers of CCA ( Figure 1.2 ). Detailed rev